The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Global Microbiome Drugs Market Research Report 2025

Global Microbiome Drugs Market Research Report 2025

Publishing Date : Mar, 2025

License Type :
 

Report Code : 1708028

No of Pages : 99

Ask Your Query

Synopsis

Microbiome Drug is a kind of medicine made with microorganisms. According to the source, it is divided into three categories: drugs derived from whole or part of microorganisms, drugs derived from microbial primary metabolites, and drugs derived from microbial secondary metabolites.

The global Microbiome Drugs market was valued at US$ 222 million in 2023 and is anticipated to reach US$ 1815.7 million by 2030, witnessing a CAGR of 34.6% during the forecast period 2024-2030.

North America and Europe hold most of market share of microbiome drugs, and North America occupies a share over 77%, on the other hand, Europe takes a share of over 22% in total. Global core microbiome drugs manufacturers include Seres Therapeutics, Assembly Biosciences, Synthetic Biologics etc.

This report aims to provide a comprehensive presentation of the global market for Microbiome Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Microbiome Drugs.

Report Scope

The Microbiome Drugs market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Microbiome Drugs market comprehensively. Regional market sizes, concerning products by Type, by Symptom, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Microbiome Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Symptom, and by regions.

Market Segmentation

By Company (Partial List)

  • Seres Therapeutics
  • Assembly Biosciences
  • Synthetic Biologics
  • Interxon
  • PureTech
  • Synlogic
  • Enterome BioScience
  • 4D Pharma
  • Second Genome
  • AOBiome
  • Rebiotix
  • Metabiomics
  • Ritter Pharmaceuticals
  • Symberix
  • OpenBiome
  • Azitra
  • Osel

Segment by Type

  • Oral Dosage Form
  • Enteric Capsules

Segment by Symptom

  • Gastrointestinal Disorders
  • Autoimmune Disorders
  • Diabetes
  • Cancer
  • Others

By Region

  • North America (United States, Canada)
  • Europe (Germany, France, U.K., Italy, Netherlands)
  • Asia-Pacific (China, Japan, South Korea, China Taiwan, Southeast Asia, India)
  • Latin America, Middle East & Africa (Latin America, Mexico, Brazil, Turkey)

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Symptom, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Microbiome Drugs companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Symptom, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

Index

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Microbiome Drugs Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Oral Dosage Form
1.2.3 Enteric Capsules
1.3 Market by Symptom
1.3.1 Global Microbiome Drugs Market Growth by Symptom: 2019 VS 2023 VS 2030
1.3.2 Gastrointestinal Disorders
1.3.3 Autoimmune Disorders
1.3.4 Diabetes
1.3.5 Cancer
1.3.6 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Microbiome Drugs Market Perspective (2019-2030)
2.2 Microbiome Drugs Growth Trends by Region
2.2.1 Global Microbiome Drugs Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Microbiome Drugs Historic Market Size by Region (2019-2024)
2.2.3 Microbiome Drugs Forecasted Market Size by Region (2025-2030)
2.3 Microbiome Drugs Market Dynamics
2.3.1 Microbiome Drugs Industry Trends
2.3.2 Microbiome Drugs Market Drivers
2.3.3 Microbiome Drugs Market Challenges
2.3.4 Microbiome Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Microbiome Drugs Players by Revenue
3.1.1 Global Top Microbiome Drugs Players by Revenue (2019-2024)
3.1.2 Global Microbiome Drugs Revenue Market Share by Players (2019-2024)
3.2 Global Microbiome Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Microbiome Drugs Revenue
3.4 Global Microbiome Drugs Market Concentration Ratio
3.4.1 Global Microbiome Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Microbiome Drugs Revenue in 2023
3.5 Microbiome Drugs Key Players Head office and Area Served
3.6 Key Players Microbiome Drugs Product Solution and Service
3.7 Date of Enter into Microbiome Drugs Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Microbiome Drugs Breakdown Data by Type
4.1 Global Microbiome Drugs Historic Market Size by Type (2019-2024)
4.2 Global Microbiome Drugs Forecasted Market Size by Type (2025-2030)
5 Microbiome Drugs Breakdown Data by Symptom
5.1 Global Microbiome Drugs Historic Market Size by Symptom (2019-2024)
5.2 Global Microbiome Drugs Forecasted Market Size by Symptom (2025-2030)
6 North America
6.1 North America Microbiome Drugs Market Size (2019-2030)
6.2 North America Microbiome Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Microbiome Drugs Market Size by Country (2019-2024)
6.4 North America Microbiome Drugs Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Microbiome Drugs Market Size (2019-2030)
7.2 Europe Microbiome Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Microbiome Drugs Market Size by Country (2019-2024)
7.4 Europe Microbiome Drugs Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Microbiome Drugs Market Size (2019-2030)
8.2 Asia-Pacific Microbiome Drugs Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Microbiome Drugs Market Size by Region (2019-2024)
8.4 Asia-Pacific Microbiome Drugs Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Microbiome Drugs Market Size (2019-2030)
9.2 Latin America Microbiome Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Microbiome Drugs Market Size by Country (2019-2024)
9.4 Latin America Microbiome Drugs Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Microbiome Drugs Market Size (2019-2030)
10.2 Middle East & Africa Microbiome Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Microbiome Drugs Market Size by Country (2019-2024)
10.4 Middle East & Africa Microbiome Drugs Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Seres Therapeutics
11.1.1 Seres Therapeutics Company Detail
11.1.2 Seres Therapeutics Business Overview
11.1.3 Seres Therapeutics Microbiome Drugs Introduction
11.1.4 Seres Therapeutics Revenue in Microbiome Drugs Business (2019-2024)
11.1.5 Seres Therapeutics Recent Development
11.2 Assembly Biosciences
11.2.1 Assembly Biosciences Company Detail
11.2.2 Assembly Biosciences Business Overview
11.2.3 Assembly Biosciences Microbiome Drugs Introduction
11.2.4 Assembly Biosciences Revenue in Microbiome Drugs Business (2019-2024)
11.2.5 Assembly Biosciences Recent Development
11.3 Synthetic Biologics
11.3.1 Synthetic Biologics Company Detail
11.3.2 Synthetic Biologics Business Overview
11.3.3 Synthetic Biologics Microbiome Drugs Introduction
11.3.4 Synthetic Biologics Revenue in Microbiome Drugs Business (2019-2024)
11.3.5 Synthetic Biologics Recent Development
11.4 Interxon
11.4.1 Interxon Company Detail
11.4.2 Interxon Business Overview
11.4.3 Interxon Microbiome Drugs Introduction
11.4.4 Interxon Revenue in Microbiome Drugs Business (2019-2024)
11.4.5 Interxon Recent Development
11.5 PureTech
11.5.1 PureTech Company Detail
11.5.2 PureTech Business Overview
11.5.3 PureTech Microbiome Drugs Introduction
11.5.4 PureTech Revenue in Microbiome Drugs Business (2019-2024)
11.5.5 PureTech Recent Development
11.6 Synlogic
11.6.1 Synlogic Company Detail
11.6.2 Synlogic Business Overview
11.6.3 Synlogic Microbiome Drugs Introduction
11.6.4 Synlogic Revenue in Microbiome Drugs Business (2019-2024)
11.6.5 Synlogic Recent Development
11.7 Enterome BioScience
11.7.1 Enterome BioScience Company Detail
11.7.2 Enterome BioScience Business Overview
11.7.3 Enterome BioScience Microbiome Drugs Introduction
11.7.4 Enterome BioScience Revenue in Microbiome Drugs Business (2019-2024)
11.7.5 Enterome BioScience Recent Development
11.8 4D Pharma
11.8.1 4D Pharma Company Detail
11.8.2 4D Pharma Business Overview
11.8.3 4D Pharma Microbiome Drugs Introduction
11.8.4 4D Pharma Revenue in Microbiome Drugs Business (2019-2024)
11.8.5 4D Pharma Recent Development
11.9 Second Genome
11.9.1 Second Genome Company Detail
11.9.2 Second Genome Business Overview
11.9.3 Second Genome Microbiome Drugs Introduction
11.9.4 Second Genome Revenue in Microbiome Drugs Business (2019-2024)
11.9.5 Second Genome Recent Development
11.10 AOBiome
11.10.1 AOBiome Company Detail
11.10.2 AOBiome Business Overview
11.10.3 AOBiome Microbiome Drugs Introduction
11.10.4 AOBiome Revenue in Microbiome Drugs Business (2019-2024)
11.10.5 AOBiome Recent Development
11.11 Rebiotix
11.11.1 Rebiotix Company Detail
11.11.2 Rebiotix Business Overview
11.11.3 Rebiotix Microbiome Drugs Introduction
11.11.4 Rebiotix Revenue in Microbiome Drugs Business (2019-2024)
11.11.5 Rebiotix Recent Development
11.12 Metabiomics
11.12.1 Metabiomics Company Detail
11.12.2 Metabiomics Business Overview
11.12.3 Metabiomics Microbiome Drugs Introduction
11.12.4 Metabiomics Revenue in Microbiome Drugs Business (2019-2024)
11.12.5 Metabiomics Recent Development
11.13 Ritter Pharmaceuticals
11.13.1 Ritter Pharmaceuticals Company Detail
11.13.2 Ritter Pharmaceuticals Business Overview
11.13.3 Ritter Pharmaceuticals Microbiome Drugs Introduction
11.13.4 Ritter Pharmaceuticals Revenue in Microbiome Drugs Business (2019-2024)
11.13.5 Ritter Pharmaceuticals Recent Development
11.14 Symberix
11.14.1 Symberix Company Detail
11.14.2 Symberix Business Overview
11.14.3 Symberix Microbiome Drugs Introduction
11.14.4 Symberix Revenue in Microbiome Drugs Business (2019-2024)
11.14.5 Symberix Recent Development
11.15 OpenBiome
11.15.1 OpenBiome Company Detail
11.15.2 OpenBiome Business Overview
11.15.3 OpenBiome Microbiome Drugs Introduction
11.15.4 OpenBiome Revenue in Microbiome Drugs Business (2019-2024)
11.15.5 OpenBiome Recent Development
11.16 Azitra
11.16.1 Azitra Company Detail
11.16.2 Azitra Business Overview
11.16.3 Azitra Microbiome Drugs Introduction
11.16.4 Azitra Revenue in Microbiome Drugs Business (2019-2024)
11.16.5 Azitra Recent Development
11.17 Osel
11.17.1 Osel Company Detail
11.17.2 Osel Business Overview
11.17.3 Osel Microbiome Drugs Introduction
11.17.4 Osel Revenue in Microbiome Drugs Business (2019-2024)
11.17.5 Osel Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables

List of Tables
Table 1. Global Microbiome Drugs Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of Oral Dosage Form
Table 3. Key Players of Enteric Capsules
Table 4. Global Microbiome Drugs Market Size Growth by Symptom (US$ Million): 2019 VS 2023 VS 2030
Table 5. Global Microbiome Drugs Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 6. Global Microbiome Drugs Market Size by Region (2019-2024) & (US$ Million)
Table 7. Global Microbiome Drugs Market Share by Region (2019-2024)
Table 8. Global Microbiome Drugs Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 9. Global Microbiome Drugs Market Share by Region (2025-2030)
Table 10. Microbiome Drugs Market Trends
Table 11. Microbiome Drugs Market Drivers
Table 12. Microbiome Drugs Market Challenges
Table 13. Microbiome Drugs Market Restraints
Table 14. Global Microbiome Drugs Revenue by Players (2019-2024) & (US$ Million)
Table 15. Global Microbiome Drugs Market Share by Players (2019-2024)
Table 16. Global Top Microbiome Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Microbiome Drugs as of 2023)
Table 17. Ranking of Global Top Microbiome Drugs Companies by Revenue (US$ Million) in 2023
Table 18. Global 5 Largest Players Market Share by Microbiome Drugs Revenue (CR5 and HHI) & (2019-2024)
Table 19. Key Players Headquarters and Area Served
Table 20. Key Players Microbiome Drugs Product Solution and Service
Table 21. Date of Enter into Microbiome Drugs Market
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Microbiome Drugs Market Size by Type (2019-2024) & (US$ Million)
Table 24. Global Microbiome Drugs Revenue Market Share by Type (2019-2024)
Table 25. Global Microbiome Drugs Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 26. Global Microbiome Drugs Revenue Market Share by Type (2025-2030)
Table 27. Global Microbiome Drugs Market Size by Symptom (2019-2024) & (US$ Million)
Table 28. Global Microbiome Drugs Revenue Market Share by Symptom (2019-2024)
Table 29. Global Microbiome Drugs Forecasted Market Size by Symptom (2025-2030) & (US$ Million)
Table 30. Global Microbiome Drugs Revenue Market Share by Symptom (2025-2030)
Table 31. North America Microbiome Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 32. North America Microbiome Drugs Market Size by Country (2019-2024) & (US$ Million)
Table 33. North America Microbiome Drugs Market Size by Country (2025-2030) & (US$ Million)
Table 34. Europe Microbiome Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 35. Europe Microbiome Drugs Market Size by Country (2019-2024) & (US$ Million)
Table 36. Europe Microbiome Drugs Market Size by Country (2025-2030) & (US$ Million)
Table 37. Asia-Pacific Microbiome Drugs Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
Table 38. Asia-Pacific Microbiome Drugs Market Size by Region (2019-2024) & (US$ Million)
Table 39. Asia-Pacific Microbiome Drugs Market Size by Region (2025-2030) & (US$ Million)
Table 40. Latin America Microbiome Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 41. Latin America Microbiome Drugs Market Size by Country (2019-2024) & (US$ Million)
Table 42. Latin America Microbiome Drugs Market Size by Country (2025-2030) & (US$ Million)
Table 43. Middle East & Africa Microbiome Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 44. Middle East & Africa Microbiome Drugs Market Size by Country (2019-2024) & (US$ Million)
Table 45. Middle East & Africa Microbiome Drugs Market Size by Country (2025-2030) & (US$ Million)
Table 46. Seres Therapeutics Company Detail
Table 47. Seres Therapeutics Business Overview
Table 48. Seres Therapeutics Microbiome Drugs Product
Table 49. Seres Therapeutics Revenue in Microbiome Drugs Business (2019-2024) & (US$ Million)
Table 50. Seres Therapeutics Recent Development
Table 51. Assembly Biosciences Company Detail
Table 52. Assembly Biosciences Business Overview
Table 53. Assembly Biosciences Microbiome Drugs Product
Table 54. Assembly Biosciences Revenue in Microbiome Drugs Business (2019-2024) & (US$ Million)
Table 55. Assembly Biosciences Recent Development
Table 56. Synthetic Biologics Company Detail
Table 57. Synthetic Biologics Business Overview
Table 58. Synthetic Biologics Microbiome Drugs Product
Table 59. Synthetic Biologics Revenue in Microbiome Drugs Business (2019-2024) & (US$ Million)
Table 60. Synthetic Biologics Recent Development
Table 61. Interxon Company Detail
Table 62. Interxon Business Overview
Table 63. Interxon Microbiome Drugs Product
Table 64. Interxon Revenue in Microbiome Drugs Business (2019-2024) & (US$ Million)
Table 65. Interxon Recent Development
Table 66. PureTech Company Detail
Table 67. PureTech Business Overview
Table 68. PureTech Microbiome Drugs Product
Table 69. PureTech Revenue in Microbiome Drugs Business (2019-2024) & (US$ Million)
Table 70. PureTech Recent Development
Table 71. Synlogic Company Detail
Table 72. Synlogic Business Overview
Table 73. Synlogic Microbiome Drugs Product
Table 74. Synlogic Revenue in Microbiome Drugs Business (2019-2024) & (US$ Million)
Table 75. Synlogic Recent Development
Table 76. Enterome BioScience Company Detail
Table 77. Enterome BioScience Business Overview
Table 78. Enterome BioScience Microbiome Drugs Product
Table 79. Enterome BioScience Revenue in Microbiome Drugs Business (2019-2024) & (US$ Million)
Table 80. Enterome BioScience Recent Development
Table 81. 4D Pharma Company Detail
Table 82. 4D Pharma Business Overview
Table 83. 4D Pharma Microbiome Drugs Product
Table 84. 4D Pharma Revenue in Microbiome Drugs Business (2019-2024) & (US$ Million)
Table 85. 4D Pharma Recent Development
Table 86. Second Genome Company Detail
Table 87. Second Genome Business Overview
Table 88. Second Genome Microbiome Drugs Product
Table 89. Second Genome Revenue in Microbiome Drugs Business (2019-2024) & (US$ Million)
Table 90. Second Genome Recent Development
Table 91. AOBiome Company Detail
Table 92. AOBiome Business Overview
Table 93. AOBiome Microbiome Drugs Product
Table 94. AOBiome Revenue in Microbiome Drugs Business (2019-2024) & (US$ Million)
Table 95. AOBiome Recent Development
Table 96. Rebiotix Company Detail
Table 97. Rebiotix Business Overview
Table 98. Rebiotix Microbiome Drugs Product
Table 99. Rebiotix Revenue in Microbiome Drugs Business (2019-2024) & (US$ Million)
Table 100. Rebiotix Recent Development
Table 101. Metabiomics Company Detail
Table 102. Metabiomics Business Overview
Table 103. Metabiomics Microbiome Drugs Product
Table 104. Metabiomics Revenue in Microbiome Drugs Business (2019-2024) & (US$ Million)
Table 105. Metabiomics Recent Development
Table 106. Ritter Pharmaceuticals Company Detail
Table 107. Ritter Pharmaceuticals Business Overview
Table 108. Ritter Pharmaceuticals Microbiome Drugs Product
Table 109. Ritter Pharmaceuticals Revenue in Microbiome Drugs Business (2019-2024) & (US$ Million)
Table 110. Ritter Pharmaceuticals Recent Development
Table 111. Symberix Company Detail
Table 112. Symberix Business Overview
Table 113. Symberix Microbiome Drugs Product
Table 114. Symberix Revenue in Microbiome Drugs Business (2019-2024) & (US$ Million)
Table 115. Symberix Recent Development
Table 116. OpenBiome Company Detail
Table 117. OpenBiome Business Overview
Table 118. OpenBiome Microbiome Drugs Product
Table 119. OpenBiome Revenue in Microbiome Drugs Business (2019-2024) & (US$ Million)
Table 120. OpenBiome Recent Development
Table 121. Azitra Company Detail
Table 122. Azitra Business Overview
Table 123. Azitra Microbiome Drugs Product
Table 124. Azitra Revenue in Microbiome Drugs Business (2019-2024) & (US$ Million)
Table 125. Azitra Recent Development
Table 126. Osel Company Detail
Table 127. Osel Business Overview
Table 128. Osel Microbiome Drugs Product
Table 129. Osel Revenue in Microbiome Drugs Business (2019-2024) & (US$ Million)
Table 130. Osel Recent Development
Table 131. Research Programs/Design for This Report
Table 132. Key Data Information from Secondary Sources
Table 133. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Microbiome Drugs Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 2. Global Microbiome Drugs Market Share by Type: 2023 VS 2030
Figure 3. Oral Dosage Form Features
Figure 4. Enteric Capsules Features
Figure 5. Global Microbiome Drugs Market Size Comparison by Symptom (2024-2030) & (US$ Million)
Figure 6. Global Microbiome Drugs Market Share by Symptom: 2023 VS 2030
Figure 7. Gastrointestinal Disorders Case Studies
Figure 8. Autoimmune Disorders Case Studies
Figure 9. Diabetes Case Studies
Figure 10. Cancer Case Studies
Figure 11. Others Case Studies
Figure 12. Microbiome Drugs Report Years Considered
Figure 13. Global Microbiome Drugs Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 14. Global Microbiome Drugs Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 15. Global Microbiome Drugs Market Share by Region: 2023 VS 2030
Figure 16. Global Microbiome Drugs Market Share by Players in 2023
Figure 17. Global Top Microbiome Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Microbiome Drugs as of 2023)
Figure 18. The Top 10 and 5 Players Market Share by Microbiome Drugs Revenue in 2023
Figure 19. North America Microbiome Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 20. North America Microbiome Drugs Market Share by Country (2019-2030)
Figure 21. United States Microbiome Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 22. Canada Microbiome Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 23. Europe Microbiome Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 24. Europe Microbiome Drugs Market Share by Country (2019-2030)
Figure 25. Germany Microbiome Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 26. France Microbiome Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 27. U.K. Microbiome Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 28. Italy Microbiome Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. Russia Microbiome Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. Nordic Countries Microbiome Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 31. Asia-Pacific Microbiome Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 32. Asia-Pacific Microbiome Drugs Market Share by Region (2019-2030)
Figure 33. China Microbiome Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 34. Japan Microbiome Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. South Korea Microbiome Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 36. Southeast Asia Microbiome Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. India Microbiome Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 38. Australia Microbiome Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 39. Latin America Microbiome Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 40. Latin America Microbiome Drugs Market Share by Country (2019-2030)
Figure 41. Mexico Microbiome Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 42. Brazil Microbiome Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 43. Middle East & Africa Microbiome Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 44. Middle East & Africa Microbiome Drugs Market Share by Country (2019-2030)
Figure 45. Turkey Microbiome Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 46. Saudi Arabia Microbiome Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 47. Seres Therapeutics Revenue Growth Rate in Microbiome Drugs Business (2019-2024)
Figure 48. Assembly Biosciences Revenue Growth Rate in Microbiome Drugs Business (2019-2024)
Figure 49. Synthetic Biologics Revenue Growth Rate in Microbiome Drugs Business (2019-2024)
Figure 50. Interxon Revenue Growth Rate in Microbiome Drugs Business (2019-2024)
Figure 51. PureTech Revenue Growth Rate in Microbiome Drugs Business (2019-2024)
Figure 52. Synlogic Revenue Growth Rate in Microbiome Drugs Business (2019-2024)
Figure 53. Enterome BioScience Revenue Growth Rate in Microbiome Drugs Business (2019-2024)
Figure 54. 4D Pharma Revenue Growth Rate in Microbiome Drugs Business (2019-2024)
Figure 55. Second Genome Revenue Growth Rate in Microbiome Drugs Business (2019-2024)
Figure 56. AOBiome Revenue Growth Rate in Microbiome Drugs Business (2019-2024)
Figure 57. Rebiotix Revenue Growth Rate in Microbiome Drugs Business (2019-2024)
Figure 58. Metabiomics Revenue Growth Rate in Microbiome Drugs Business (2019-2024)
Figure 59. Ritter Pharmaceuticals Revenue Growth Rate in Microbiome Drugs Business (2019-2024)
Figure 60. Symberix Revenue Growth Rate in Microbiome Drugs Business (2019-2024)
Figure 61. OpenBiome Revenue Growth Rate in Microbiome Drugs Business (2019-2024)
Figure 62. Azitra Revenue Growth Rate in Microbiome Drugs Business (2019-2024)
Figure 63. Osel Revenue Growth Rate in Microbiome Drugs Business (2019-2024)
Figure 64. Bottom-up and Top-down Approaches for This Report
Figure 65. Data Triangulation
Figure 66. Key Executives Interviewed

Published By : QY Research

Why ‘The Market Reports’

In Business: Pre Sales Support: Post Sales Support: Turn Around Time: Clients Served: Clients Assisted: Client Types: Payment: Partners with: Number of reports: Custom Research: Report Availability: Report Delivery Format: Security:

Payments Accepted From

Connect with us at

Complete Secure Website

SiteLock